drugset / Trial / NCT00135629

Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever

NCT00135629 ↗

Phase 3 Completed 18 enrolled Imperial College London ALK-Abelló A/S · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to determine at which point in the dosing regime grass pollen immunotherapy causes a significant reduction in the late skin response to allergen challenge. A once weekly cluster regimen of 2 injections per visit was employed during the up-dosing phase, followed by monthly maintenance injections of 100,000 SQ units. Symptom scores and need of rescue medication were recorded by patients during the study period. The size of early and late cutaneous response to allergen challenge was recorded and measured by a physician.

Timeline

Start
2002-10
Primary completion
2008-01
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Alutard SQ Vaccine 100000 unknown —